Open Access Case report

Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report

Piero Farruggia1*, Serena Tropia1, Sonia Cannella1, Giuseppa Bruno1, Gaspare Oddo2 and Paolo D’Angelo1

Author Affiliations

1 Oncology Department, Pediatric Hematology and Oncology Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Piazza N. Leotta 4, Palermo, 90127, Italy

2 Clinic Department, Pharmaceutical Laboratory, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Piazza N. Leotta 4, Palermo, 90127, Italy

For all author emails, please log on.

Journal of Medical Case Reports 2012, 6:128 doi:10.1186/1752-1947-6-128

Published: 14 May 2012

Abstract

Introduction

Vincristine is an antineoplastic drug with a well known efficacy for the treatment of acute lymphoblastic leukemia and many solid tumors. No more than 20 pediatric patients with vincristine-induced vocal cord palsy have been reported, and to the best of our knowledge this is the first case where glutamic acid was administered with the aim of preventing a relapse of laryngeal dysfunction.

Case presentation

The larynx paralysis presented with hoarseness and stridor in a Caucasian 18-month-old girl and spontaneously resolved in about a month. In order to administer a subsequent full dose of vincristine, our patient received oral glutamic acid whose efficacy against vincristine neurological side effects has been previously reported.

Conclusions

Since in our patient the amino acid proved to be ineffective in the prevention of laryngeal paralysis relapse, we suggest that a dose reduction of vincristine should be preferred by oncologists as an initial approach after a case of drug-induced vocal cord palsy.

Keywords:
Glutamic acid; Neuropathy; Vincristine; Vocal cord palsy